Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate
Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate
再鼎医药2024年第二季度每股美国通用会计准则亏损$(0.82)，未达到$(0.70)的预期，销售额为10050.4万元，超出了9313.6万元的预期。
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.82) per ADS which missed the analyst consensus estimate of $(0.70) by 17.14 percent. This is a 34.4 percent increase over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $100.504 million which beat the analyst consensus estimate of $93.136 million by 7.91 percent. This is a 45.95 percent increase over sales of $68.864 million the same period last year.
再鼎医药（纳斯达克：ZLAB）报告每个美国存托股份ADS的季度亏损为0.82美元，比分析师共识估计的0.70美元低了17.14％。这比去年同期每股亏损1.25美元增长了34.4％。该公司报告的季度销售额为1.00504亿美元，比分析师共识估计的9313.6万美元高7.91％。这是销售额同比增长45.95％的结果。